The order in which treatments are introduced profoundly affects long-term outcomes, patient psychology, and how the face evolves
Core Principles of Strategic Sequencing
Assess Movement Before Volume
Before adding filler to any region, understand how underlying muscles work. Botulinum often precedes or informs filler placement to establish baseline movement first.
Start Central, Expand Peripheral
Treat the central face first to establish balance there. Malar projection first, then under-eye, then temples. Central balance guides appropriate peripheral volume distribution.
Correctional Before Preventative
Correct the most visible/problematic area first. Once settled and patient adapts psychologically, address preventative areas. Address the concern that brought the patient in before addressing concerns they hadn’t articulated.
Single-Area Baseline Before Multi-Area Treatment
A patient’s first experience with an injectable in a new region should be conservative and isolated. This allows assessment of response, psychology, and integration before layering additional treatments.
Typical Sequencing Pathways
Beyond These Pathways
These three pathways are common archetypes, but your actual sequencing may follow different logic based on your stated goals, structural presentation, and psychological readiness. The Core Method applies these principles to any pathway: assess movement baseline before adding volume; treat the central face first to establish balance there; address your stated primary concern before addressing concerns you hadn’t mentioned; introduce single-region treatments conservatively before layering multiple areas. The pathways above are examples, not prescriptions. Principles matter more than templates.
Long-Term Sequencing Over Years
Each treatment cycle should add no more volume than was absorbed in the interim. Cumulative volume increase of ~0.03mL per year is appropriate. Escalation beyond this is unsustainable.
Product Sequencing: Botulinum Before or After Filler?
The order matters less than the reasoning. Filler-first works when primary concern is volume loss. Botulinum-first works when primary concern is expression lines. Simultaneous introduction to different regions is acceptable if well-reasoned and documented.
Strategic product-choice sequencing: Botulinum-first often works for expression-focused patients because movement change is most noticeable immediately, and psychological adaptation is easier when the patient can see the effect clearly. Filler-first often works for volume-loss-focused patients because structural change is immediate and undeniable. Simultaneous introduction to different regions (e.g., botulinum to glabella + filler to malar) is acceptable if each region has independent clinical justification. The key is intentionality: each product and region enters at a moment chosen for clinical coherence and psychological readiness, not just convenience.
Frequently asked questions
Why does the order of treatment matter?
Order affects patient psychology, cumulative outcomes, and how the face evolves long-term. Strategic sequencing prevents over-treatment and maintains facial authenticity.
What if my sequencing plan changes?
Plans are guidelines, not protocols. Patient satisfaction and clinical assessment override the planned sequence. Delays, accelerations, and skipped phases are appropriate when clinically justified.
Should botulinum or filler be done first?
Either, depending on your primary concern. Botulinum is safer entry-point psychologically (reversible). Filler directly addresses volume loss. Choose based on what matters most to you.
How do I know if I’m being over-treated?
Watch for escalating doses at each cycle, requests for larger volumes or shorter intervals, or practitioner adding new regions without clear clinical reason. Appropriate sequencing maintains or slightly decreases dose per cycle.